Alan G. Sutherland

Dr. Alan G. Sutherland is a Practitioner in Residence in the Chemistry and Chemical & Biomedical Engineering Department at the University of New Haven since 2011. He also works as a Medicinal Chemist at L2 Diagnostics in New Haven. Prior to joining UNH, he held research roles at Wyeth Research (1995–2010), where he advanced from Senior to Principal Research Scientist, and earlier faculty positions at the University of Exeter and University of North London in the UK.

• B.Sc. in Chemistry, University of Edinburgh
• Ph.D. in Chemistry, University of East Anglia

Dr. Sutherland's research focuses on developing anti-inflammatory, antibacterial, antiviral, and antitumor agents. He leads a NEI-supported program on macular degeneration treatments and contributes to NIH and DoD-funded projects as a Co-Investigator. His work integrates medicinal chemistry, biocatalysis, and structure-based drug design to target diseases like AIDS, Gram-positive bacterial infections, and cancer.

Key publication trends include anti-inflammatory agents, glycopeptide antibiotics, asymmetric synthesis methods, enzymatic resolutions, and inhibitors of bacterial cell division proteins (FtsZ/ZipA). His studies span organic chemistry, pharmacology, and biocatalysis, emphasizing practical applications in drug discovery.